Tech Company Financing Transactions
Arixa Pharmaceuticals Funding Round
Arixa Pharmaceuticals secured a $8 million Seed funding round on 5/2/2018. Investors included private investors.
Transaction Overview
Company Name
Announced On
5/2/2018
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Seed
Investors
Proceeds Purpose
With the completion of the financing, the company intends to conduct a Phase 1 human clinical study of its lead candidate, ARX-1796, a proprietary, orally available prodrug of Avibactam, an FDA-approved beta-lactamase inhibitor that previously could be delivered only by intravenous injection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Palo Alto, CA 94020
USA
Palo Alto, CA 94020
USA
Phone
Undisclosed
Website
Email Address
Overview
Arixa Pharmaceuticals is developing oral antibiotics for resistant Gram-negative infections using our proprietary prodrug technology. We have successfully created a series of safe oral prodrugs of avibactam, a ß-lactamase inhibitor approved by FDA in 2015 as component of AVYCAZ.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Freund
Chief Scientific Officer
Eric Gordon
Co-Founder
Joaquim Trias
Browse more venture capital transactions:
Prev: 5/2/2018: SkyKick venture capital transaction
Next: 5/2/2018: OwnerIQ venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs